Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2014

Open Access 01-12-2014 | Case report

Myocardial fibrosis as the first sign of cardiac involvement in a male patient with Fabry disease: report of a clinical case and discussion on the utility of the magnetic resonance in Fabry pathology

Authors: Annalisa Sechi, Gaetano Nucifora, Gianluca Piccoli, Andrea Dardis, Bruno Bembi

Published in: BMC Cardiovascular Disorders | Issue 1/2014

Login to get access

Abstract

Background

Cardiovascular magnetic resonance (CMR) with late gadolinium enhancement (LGE) imaging is increasingly used to assess myocardial involvement in patients with Fabry disease, an X linked lipid storage disorder. However, it is often proposed as an optional tool. A different cardiomyopathic disease progression between male and female patients was hypothesised in previous studies, as in female myocardial fibrosis was found without left ventricular (LV) hypertrophy, while myocardial fibrosis was always detected in association to LV hypertrophy in men.

Case presentation

A male Caucasian patient, 19 years old, diagnosed through a family-based molecular screening, presented with LGE of the LV inferolateral wall evidenced at the CMR, without LV hypertrophy, or other clinical signs of the disease.

Conclusion

This is the first report of cardiac fibrosis as the first sign of organ involvement in a male patient with Fabry disease. This finding stresses the importance of performing CMR with LGE imaging for the initial staging and monitoring of Fabry patients of both genders.
Appendix
Available only for authorised users
Literature
1.
go back to reference Desnick R, Ioannou Y, Eng C: Alpha-Galactosidase A deficiency: Fabry disease. The Metabolic and Molecular Bases of Inherited Disease. Edited by: Scriver CR BA, Sly WS, Valle D. 2001, New York: McGraw-Hill, 3733-3774. 8 Desnick R, Ioannou Y, Eng C: Alpha-Galactosidase A deficiency: Fabry disease. The Metabolic and Molecular Bases of Inherited Disease. Edited by: Scriver CR BA, Sly WS, Valle D. 2001, New York: McGraw-Hill, 3733-3774. 8
2.
go back to reference Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M, European FOS Investigators: Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet. 2006, 43: 347-352.CrossRefPubMed Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M, European FOS Investigators: Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet. 2006, 43: 347-352.CrossRefPubMed
3.
go back to reference Martins AM, D'Almeida V, Kyosen SO, Takata ET, Delgado AG, Gonçalves AM, Benetti Filho CC, Martini Filho D, Biagini G, Pimentel H, Abensur H, Guimarães HC, Gomes JG, Sobral Neto J, D'Almeida LO, Carvalho LR, Harouche MB, Maldonado MC, Nascimento OJ, Montoril PS, Bastos RV: Guidelines to diagnosis and monitoring of Fabry disease and review of treatment experiences. J Pediatr. 2009, 155 (4 Suppl): S19-S31.CrossRefPubMed Martins AM, D'Almeida V, Kyosen SO, Takata ET, Delgado AG, Gonçalves AM, Benetti Filho CC, Martini Filho D, Biagini G, Pimentel H, Abensur H, Guimarães HC, Gomes JG, Sobral Neto J, D'Almeida LO, Carvalho LR, Harouche MB, Maldonado MC, Nascimento OJ, Montoril PS, Bastos RV: Guidelines to diagnosis and monitoring of Fabry disease and review of treatment experiences. J Pediatr. 2009, 155 (4 Suppl): S19-S31.CrossRefPubMed
4.
go back to reference Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C: Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int. 2006, 69: 1216-1221. 10.1038/sj.ki.5000208.CrossRefPubMed Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C: Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int. 2006, 69: 1216-1221. 10.1038/sj.ki.5000208.CrossRefPubMed
5.
go back to reference Engelen MA, Brand E, Baumeister TB, Marquardt T, Duning T, Osada N, Schaefer RM, Stypmann J: Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: a retrospective cohort study of the Fabry Munster Study (FaMuS) data. BMJ Open. 2012, 21: 2(6)- Engelen MA, Brand E, Baumeister TB, Marquardt T, Duning T, Osada N, Schaefer RM, Stypmann J: Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: a retrospective cohort study of the Fabry Munster Study (FaMuS) data. BMJ Open. 2012, 21: 2(6)-
6.
go back to reference Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, Beck M, Sunder-Plassmann G, FOS Investigators: Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. J Med Genet. 2009, 46: 548-552. 10.1136/jmg.2008.065904.CrossRefPubMed Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, Beck M, Sunder-Plassmann G, FOS Investigators: Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. J Med Genet. 2009, 46: 548-552. 10.1136/jmg.2008.065904.CrossRefPubMed
7.
go back to reference Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ, Leed PJ, Elliott PM: Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J. 2003, 24: 2151-2155. 10.1016/j.ehj.2003.09.017.CrossRefPubMed Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ, Leed PJ, Elliott PM: Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J. 2003, 24: 2151-2155. 10.1016/j.ehj.2003.09.017.CrossRefPubMed
8.
go back to reference Weidemann F, Breunig F, Beer M, Sandstede J, Störk S, Voelker W, Ertl G, Knoll A, Wanner C, Strotmann JM: The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J. 2005, 26: 1221-1227. 10.1093/eurheartj/ehi143.CrossRefPubMed Weidemann F, Breunig F, Beer M, Sandstede J, Störk S, Voelker W, Ertl G, Knoll A, Wanner C, Strotmann JM: The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J. 2005, 26: 1221-1227. 10.1093/eurheartj/ehi143.CrossRefPubMed
9.
go back to reference Niemann M, Herrmann S, Hu K, Breunig F, Strotmann J, Beer M, Machann W, Voelker W, Ertl G, Wanner C, Weidemann F: Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging. 2011, 4: 592-601. 10.1016/j.jcmg.2011.01.020.CrossRefPubMed Niemann M, Herrmann S, Hu K, Breunig F, Strotmann J, Beer M, Machann W, Voelker W, Ertl G, Wanner C, Weidemann F: Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging. 2011, 4: 592-601. 10.1016/j.jcmg.2011.01.020.CrossRefPubMed
10.
go back to reference Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, Grabowski G, Packman S, Wilcox WR: Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. 2003, 138: 338-346. 10.7326/0003-4819-138-4-200302180-00014.CrossRefPubMed Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, Grabowski G, Packman S, Wilcox WR: Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. 2003, 138: 338-346. 10.7326/0003-4819-138-4-200302180-00014.CrossRefPubMed
11.
go back to reference Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, Bultas J, Lee P, Sims K, Brodie SE, Pastores GM, Strotmann JM, Wilcox WR: Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006, 8: 539-548. 10.1097/01.gim.0000237866.70357.c6.CrossRefPubMed Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, Bultas J, Lee P, Sims K, Brodie SE, Pastores GM, Strotmann JM, Wilcox WR: Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006, 8: 539-548. 10.1097/01.gim.0000237866.70357.c6.CrossRefPubMed
12.
go back to reference Gange CA, Link MS, Maron MS: Utility of cardiovascular magnetic resonance in the diagnosis of Anderson-Fabry disease. Circulation. 2009, 120: e96-e97. 10.1161/CIRCULATIONAHA.109.849828.CrossRefPubMed Gange CA, Link MS, Maron MS: Utility of cardiovascular magnetic resonance in the diagnosis of Anderson-Fabry disease. Circulation. 2009, 120: e96-e97. 10.1161/CIRCULATIONAHA.109.849828.CrossRefPubMed
13.
go back to reference Nucifora G, Miani D, Di Chiara A, Piccoli G, Artico J, Puppato M, Slavich G, De Biasio M, Gasparini D, Proclemer A: Infarct-like acute myocarditis: relation between electrocardiographic findings and myocardial damage as assessed by cardiac magnetic resonance imaging. Clin Cardiol. 2013, 36: 146-152. 10.1002/clc.22088.CrossRefPubMed Nucifora G, Miani D, Di Chiara A, Piccoli G, Artico J, Puppato M, Slavich G, De Biasio M, Gasparini D, Proclemer A: Infarct-like acute myocarditis: relation between electrocardiographic findings and myocardial damage as assessed by cardiac magnetic resonance imaging. Clin Cardiol. 2013, 36: 146-152. 10.1002/clc.22088.CrossRefPubMed
14.
go back to reference Thompson RB, Chow K, Khan A, Chan A, Shanks M, Paterson I, Oudit GY: T1 mapping with cardiovascular MRI is highly sensitive for fabry disease independent of hypertrophy and sex. Circ Cardiovasc Imaging. 2013, 6: 637-645. 10.1161/CIRCIMAGING.113.000482.CrossRefPubMed Thompson RB, Chow K, Khan A, Chan A, Shanks M, Paterson I, Oudit GY: T1 mapping with cardiovascular MRI is highly sensitive for fabry disease independent of hypertrophy and sex. Circ Cardiovasc Imaging. 2013, 6: 637-645. 10.1161/CIRCIMAGING.113.000482.CrossRefPubMed
15.
go back to reference Sengupta PP, Korinek J, Belohlavek M, Narula J, Vannan MA, Jahangir A, Khandheria BK: Left ventricular structure and function: basic science for cardiac imaging. J Am Coll Cardiol. 2006, 48: 1988-2001. 10.1016/j.jacc.2006.08.030.CrossRefPubMed Sengupta PP, Korinek J, Belohlavek M, Narula J, Vannan MA, Jahangir A, Khandheria BK: Left ventricular structure and function: basic science for cardiac imaging. J Am Coll Cardiol. 2006, 48: 1988-2001. 10.1016/j.jacc.2006.08.030.CrossRefPubMed
16.
go back to reference Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Störk S, Voelker W, Ertl G, Wanner C, Strotmann J: Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation. 2009, 119: 524-529. 10.1161/CIRCULATIONAHA.108.794529.CrossRefPubMed Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Störk S, Voelker W, Ertl G, Wanner C, Strotmann J: Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation. 2009, 119: 524-529. 10.1161/CIRCULATIONAHA.108.794529.CrossRefPubMed
17.
go back to reference Beer M, Weidemann F, Breunig F, Knoll A, Koeppe S, Machann W, Hahn D, Wanner C, Strotmann J, Sandstede J: Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol. 2006, 97: 1515-1518. 10.1016/j.amjcard.2005.11.087.CrossRefPubMed Beer M, Weidemann F, Breunig F, Knoll A, Koeppe S, Machann W, Hahn D, Wanner C, Strotmann J, Sandstede J: Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol. 2006, 97: 1515-1518. 10.1016/j.amjcard.2005.11.087.CrossRefPubMed
Metadata
Title
Myocardial fibrosis as the first sign of cardiac involvement in a male patient with Fabry disease: report of a clinical case and discussion on the utility of the magnetic resonance in Fabry pathology
Authors
Annalisa Sechi
Gaetano Nucifora
Gianluca Piccoli
Andrea Dardis
Bruno Bembi
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2014
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/1471-2261-14-86

Other articles of this Issue 1/2014

BMC Cardiovascular Disorders 1/2014 Go to the issue